News of Note—Moderna’s combo vaccine, Seqirus revenue and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Moderna’s mRNA-1653, a combo vaccine designed to protect against human metapneumovirus and parainfluenza type 3, boosted serum neutralization titers against the two viruses, according to the company’s interim phase 1 data report. Release

> Seqirus’ revenue for the six months ended Dec. 31 grew 21% at constant currency to reach $949 million, driven largely by its flu vaccines, parent company CSL said in a half-year report. Report

> Vaxart plans to start phase 1 bivalent and phase 2 monovalent challenge studies for its oral norovirus vaccine in the first half of 2019, CEO Wouter Latour, M.D., said as the company reported fourth-quarter financial results. Release

> Health experts are calling on Facebook to stem the rise of anti-vaccination groups in which members post misinformation in a closed circle. The Guardian article

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.